Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novartis Extends RNAi Pact with Alnylam | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Novartis Extends RNAi Pact with Alnylam

Novartis has extended its RNAi therapeutics collaboration with Alnylam Pharmaceuticals for a fifth and final year, through October 2010.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis has extended its RNAi therapeutics collaboration with Alnylam Pharmaceuticals for a fifth and final year, through October 2010. The alliance, initiated in 2005, is focused on the discovery, development, and commercialization of RNAi therapeutics toward Novartis-selected disease gene targets.

Both companies are responsible for RNAi discovery activities and Novartis is responsible for development and commercialization of RNAi therapeutic products. Novartis will continue to fund R&D efforts. Novartis retains the right to exercise a non-exclusive platform from Alnylam in exchange for certain license payments, as well as an undisclosed payment and future milestones and royalties. Also, Novartis retains certain rights to purchase Alnylam equity up to its current ownership level, which is approximately 13%.

“We are thrilled that Novartis has once again elected to extend our alliance, this time for a fifth and final planned year,” said John Maraganore, Ph.D., chief executive officer of Alnylam. “This is the second extension that Novartis has elected to make, which we believe reflects the success of our collaborative efforts as well as the scientific progress we have made in advancing our innovative technology to patients. Novartis has been an industry pioneer in recognizing the potential of RNAi therapeutics as a new class of medicines, and we look forward to continuing our work with them.”

Sign up today for Contracting & Outsourcing 2009!
stagging_cp.rodpub.com/2009conference

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters